Scopio Labs

From an analog microscope to a digital slide

Scopio Labs was founded in 2015, according to Itai Hayut's biography on the ICI conference website. Hayut and Erez Na'aman, the founders shown on the company's website, came from physics and medical technology. As they describe it, the idea came from watching lab teams count cells and assess their shape under a microscope. They wanted to analyze the information with software, but first they had to develop a way to scan the slide at the right quality. So the company also built the imaging layer, and not only software that receives a ready-made image from another device.

What the AI examines

The platform combines computational imaging with deep learning to analyze morphology, meaning the shape of the cells and their visible features. The system turns a glass slide into a digital image that can be enlarged and examined on a screen. The image analysis helps count and classify cells, and the expert can move between areas and also check the context around a given cell. According to the company's website, the products allow viewing of the whole slide, and not just a collection of isolated images. That way the raw material of the test stays accessible to the team alongside the analysis results. The scanning and analysis are used in hematology tests, where the shape of the cell matters alongside the number of cells. The expert can also examine neighboring cells on the same digital slide.

Shared review between labs

The digital approach lets teams consult over their secure network without moving the physical slide or bringing an expert to the lab. The website shows labs such as Mount Sinai, PathGroup and Ichilov. A PathGroup testimonial describes the difficulty of scanning slides at 100x magnification as a reason for adopting the system. Other testimonials highlight moving between areas of the slide and sharing images between sites. These are descriptions of use published by the company, not sales figures.

Funding and the autonomous product in development

On 24 July 2025, CTech reported an additional $10 million investment from Viola Growth. The extension brought the fourth funding round to $52 million. The money was intended to advance CBM, a product for autonomous analysis of blood morphology. In the article, the company distinguished between the digital system that already assists professionals and the plan to produce an automatic result. As of a check in September 2026, the company still presents the product as in development.

Approval belongs to a specific product

The official website makes an explicit regulatory distinction. The application for peripheral blood smears is cleared by the FDA and carries the European CE mark. The application for bone marrow aspirates carries the European mark, and according to CAP Today received FDA clearance through the De Novo pathway in April 2024, although on the company's website it is still marked as pending clearance in the United States. CBM is in development and is not available for in vitro diagnostic use. In other words, the imaging applications that assist the expert are approved, and the autonomous analysis is not yet available.